Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL6ST | P40189 | 5/20 | 0.43 |
| ▸ | ACE | P12821 | 5/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083744 | 0.80 | MAPK1 (0.36) | IL6STACENAAA | |
| SCHEMBL21075769 | 0.80 | MAPK1 (0.36) | IL6STACENAAA | |
| SCHEMBL6806230 | 0.80 | NAAA (0.33) | IL6STACENAAA | |
| SCHEMBL11305102 | 0.78 | ACE (0.48) | ACE | |
| SCHEMBL21154125 | 0.77 | IL6ST (0.67) | IL6STSTAT3PIK3CD | |
| SCHEMBL21153766 | 0.77 | IL6ST (0.67) | IL6STSTAT3PIK3CD | |
| SCHEMBL19083745 | 0.76 | NAAA (0.33) | IL6STACENAAA | |
| SCHEMBL11305105 | 0.73 | ACE (0.35) | IL6STACESTAT3PIK3CDNAAA | |
| SCHEMBL21153492 | 0.73 | ALDH1A1 (0.51) | IL6STNAAA | |
| SCHEMBL21153784 | 0.73 | ALDH1A1 (0.51) | IL6STNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | IL6ST 1943/4885ACE 1083/4885STAT3 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.